Doran S Ksienski

Learn More
Rates of metastatectomy vary among patients with liver-only metastatic colorectal cancer (MCRC). This study describe predictors of referral to a hepatobiliary surgeon (HBS) and hepatic resection in a population-based setting. Patients referred to the British Columbia Cancer Agency (BCCA) with synchronous or relapsed MCRC isolated to the liver in 2002–2004(More)
Just over a decade ago, gastrointestinal tumours were a poorly understood mesenchymal neoplasm unsuccessfully treated with chemotherapy. Cytotoxic therapy for advanced disease yielded response rates of 10% and median survival of just 18 months. However, the discovery of KIT and platelet derived growth factor receptor alpha (PDGFRA) mutations as oncogenic(More)
OBJECTIVE The Influenza Prevention Policy ("the Policy") aims to increase seasonal influenza vaccination coverage among British Columbia (BC) health care workers (HCWs). PARTICIPANTS HCWs who work in publicly funded facilities and attend patient care areas. SETTING The Policy was announced in August 2012 and took effect province-wide during the 2012/13(More)
e15070 Background: Randomized clinical trials have demonstrated a robust survival benefit of AT for node positive (stage III) CC patients; similar evidence for node-negative (stage II) patients is lacking. While guidelines recommend AT for stage III colon cancer but AT is not a routine recommendation for stage II. Actual practice of the evidence varies and(More)
BACKGROUND Uterine sarcomas account for approximately 3% to 7% of all uterine malignancies. Distinguishing benign and malignant myomas based on physical examination and imaging alone is challenging. CASE A postmenopausal woman with a history of leiomyomas presented to the Emergency Department with chest pain and a right upper lobe lung mass. Blood tests(More)
e16538 Background: Evidence suggests that XELOX (NO16968 XELOXA) may have similar efficacy as mFOLFOX6 in the adjuvant treatment of colon cancer. Because XELOX is partly administered orally and is associated with a 3-week rather than a 2-week treatment cycle, we conducted a CMA from the healthcare payer and societal perspectives in order to evaluate the(More)
  • 1